Beirne Wealth Consulting Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Beirne Wealth Consulting Services’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59K	Hold	45,000	–	–	0.01%	102
2026 Q1	$71.1K	Hold	45,000	–	–	0.02%	104
2025 Q4	$75.2K	Hold	45,000	–	–	0.02%	106
2025 Q3	$76K	Hold	45,000	–	–	0.02%	226
2025 Q2	$40.8K	Hold	45,000	–	–	0.01%	103
2025 Q1	$20.3K	Hold	45,000	–	–	0.01%	102
2024 Q4	$22.6K	Hold	45,000	–	–	0.01%	98
2024 Q3	$40.7K	Hold	45,000	–	–	0.01%	101
2024 Q2	$44.9K	Hold	45,000	–	–	0.02%	97
2024 Q1	$66.6K	Hold	45,000	–	–	0.03%	98
2023 Q4	$49K	Hold	45,000	–	–	0.02%	151
2023 Q3	$63.5K	Hold	45,000	–	–	0.05%	91
2023 Q2	$63.5K	Hold	45,000	–	–	0.05%	91
2023 Q1	$67.5K	Hold	45,000	–	–	0.05%	95
2022 Q4	$52.6K	Hold	45,000	–	–	0.03%	88
2022 Q3	$51K	Hold	45,000	–	–	0.02%	97
2022 Q2	$71K	Hold	45,000	–	–	0.05%	89
2022 Q1	$70K	Hold	45,000	–	–	0.04%	93
2021 Q4	$110K	Hold	45,000	–	–	0.06%	99
2021 Q3	$113K	Hold	45,000	–	–	0.06%	107
2021 Q2	$128K	Hold	45,000	–	–	0.07%	109
2021 Q1	$106K	Hold	45,000	–	–	0.06%	104
2020 Q4	$79K	Hold	45,000	–	–	0.04%	160
2020 Q3	$42K	Sell	45,000 -25,000	-36%	-$22.1K	0.02%	136
2020 Q2	$61K	Buy	70,000 +25,000	+56%	+$22K	0.05%	75
2020 Q1	$37K	Hold	45,000	–	–	0.04%	70
2019 Q4	$40K	Hold	45,000	–	–	0.04%	93
2019 Q3	$44K	Hold	45,000	–	–	0.04%	135
2019 Q2	$50K	Buy	45,000 +20,000	+80%	+$23K	0.04%	132
2019 Q1	$33K	Buy	25,000 +5,000	+25%	+$6.22K	0.03%	186
2018 Q4	$18K	Buy	+20,000	New	+$30.6K	0.02%	177

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Beirne Wealth Consulting Services's LCTX Position: Q2 2026 in Review

Beirne Wealth Consulting Services held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 45,000 shares worth $59K. The position accounts for 0.01% of the portfolio, ranked #102.

Beirne Wealth Consulting Services first reported a position in LCTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $128K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Beirne Wealth Consulting Services held 45,000 shares of Lineage Cell Therapeutics worth $59K as of Q2 2026.
Beirne Wealth Consulting Services left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up 0.01% of Beirne Wealth Consulting Services's portfolio in Q2 2026, its #102 holding.
Beirne Wealth Consulting Services first reported a position in Lineage Cell Therapeutics in Q4 2018 and has held it in 31 quarters since.
Beirne Wealth Consulting Services's Lineage Cell Therapeutics position peaked at $128K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Beirne Wealth Consulting Services's 13F filing for Q2 2026, filed 15 Jul 2026.